M
Mathias Werner
Researcher at University of British Columbia
Publications - 24
Citations - 1751
Mathias Werner is an academic researcher from University of British Columbia. The author has contributed to research in topics: Sarcoma & Osteosarcoma. The author has an hindex of 12, co-authored 24 publications receiving 1365 citations.
Papers
More filters
Journal ArticleDOI
Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs
N. Fuchs,Stefan S. Bielack,D Epler,P Bieling,G. Delling,Dieter Körholz,Norbert Graf,U. Heise,Heribert Jürgens,Rainer Kotz,M. Salzer-Kuntschik,P. Weinel,Mathias Werner,K. Winkler +13 more
TL;DR: In a multicenter setting, intensive treatment of osteosarcoma according to protocol COSS-86 led to long-term disease-free survival for two thirds of patients and saw no benefit of using the intraarterial route to administer cisplatin.
Journal ArticleDOI
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Neyssa Marina,Sigbjørn Smeland,Stefan S. Bielack,Mark L. Bernstein,Gordana Jovic,Mark Krailo,Jane Hook,Jane Hook,Carola A.S. Arndt,Henk van den Berg,Bernadette Brennan,Bénédicte Brichard,Kenneth L.B. Brown,Trude Butterfass-Bahloul,Gabriele Calaminus,Heike E. Daldrup-Link,Mikael Eriksson,Mark C. Gebhardt,Hans Gelderblom,Joachim Gerss,Robert E. Goldsby,Allen M. Goorin,Richard Gorlick,Holcombe E. Grier,Juliet Hale,Kirsten Sundby Hall,Jendrik Hardes,Douglas S. Hawkins,Knut Helmke,Pancras C.W. Hogendoorn,Michael S. Isakoff,Katherine A. Janeway,Heribert Jürgens,Leo Kager,Thomas Kühne,Ching C. Lau,Patrick J. Leavey,Stephen L. Lessnick,Leo Mascarenhas,Paul A. Meyers,Hubert Mottl,Michaela Nathrath,Zsuzsanna Papai,R. Lor Randall,Peter Reichardt,Marleen Renard,Akmal Safwat,Cindy L. Schwartz,Michael C. Stevens,Sandra J. Strauss,Lisa A. Teot,Mathias Werner,Matthew R. Sydes,Jeremy Whelan +53 more
TL;DR: The EURAMOS-1 results do not support the addition of ifosfamide and etoposide in patients with poorly responding osteosarcoma, and the primary outcome measure was event-free survival measured in the intention-to-treat population.
Journal ArticleDOI
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan S. Bielack,Sigbjørn Smeland,Jeremy Whelan,Neyssa Marina,Gordana Jovic,Jane Hook,Mark Krailo,Mark C. Gebhardt,Zsuzsanna Papai,James O. Meyer,Helen Nadel,R. Lor Randall,Claudia Deffenbaugh,Rajaram Nagarajan,Bernadette Brennan,G. Douglas Letson,Lisa A. Teot,Allen M. Goorin,Daniel Baumhoer,Leo Kager,Mathias Werner,Ching C. Lau,Kirsten Sundby Hall,Hans Gelderblom,Paul A. Meyers,Richard Gorlick,Reinhard Windhager,Knut Helmke,Mikael Eriksson,Peter M. Hoogerbrugge,Paula J. Schomberg,Per-Ulf Tunn,Thomas Kühne,Heribert Jürgens,Henk van den Berg,Tom Böhling,Susan Picton,Marleen Renard,Peter Reichardt,Joachim Gerss,Trude Butterfass-Bahloul,Carol D. Morris,Pancras C.W. Hogendoorn,Beatrice Seddon,Gabriele Calaminus,Maria Michelagnoli,Catharina Dhooge,Matthew R. Sydes,Mark L. Bernstein +48 more
TL;DR: Investigation of maintenance therapy with pegylated interferon alfa-2b in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy found that MAP plus IFN-α-2B was not statistically different from MAP alone.
Book ChapterDOI
Osteosarcoma: the COSS experience.
Stefan S. Bielack,Herbert Jürgens,Gernot Jundt,Matthias Kevric,Thomas Kühne,Peter Reichardt,Andreas Zoubek,Mathias Werner,Winfried Winkelmann,Rainer Kotz +9 more
TL;DR: While survival expectancies improved from the first to the second half of the recruitment period, no further improvement was evident within the latter period, and tumor response to preoperative chemotherapy was of independent prognostic significance.
Journal ArticleDOI
The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols
Dimosthenis Andreou,Stefan S. Bielack,Dorothe Carrle,Matthias Kevric,Rainer Kotz,W. Winkelmann,Gernot Jundt,Mathias Werner,S. Fehlberg,Leo Kager,Thomas Kühne,Susanna Lang,M. Dominkus,G. U. Exner,Jendrik Hardes,A. Hillmann,V. Ewerbeck,U. Heise,Peter Reichardt,Per-Ulf Tunn +19 more
TL;DR: Surgical treatment at centers with small patient volume and additional surgery in the primary tumor area, other than biopsy and tumor resection, were significantly associated with a higher rate of ablative surgery.